BACKGROUND: Human leukocyte antigen (HLA) class I and II genotype is associated with clearance of hepatitis C virus (HCV) infection, but little is known regarding its relation with HCV viral load or risk of liver disease in patients with persistent HCV infection. METHODS: High-resolution HLA class I and II genotyping was conducted in a prospective cohort of 519 human immunodeficiency virus (HIV)-seropositive and 100 HIV-seronegative women with persistent HCV infection. The end points were baseline HCV viral load and 2 noninvasive indexes of liver disease, fibrosis-4 (FIB-4), and the aspartate aminotransferase to platelet ratio index (APRI), measured at baseline and prospectively. RESULTS: DQB1*0301 was associated with low baseline HCV load (β = -.4; 95% confidence interval [CI], -.6 to -.3; P < .00001), as well as with low odds of FIB-4-defined (odds ratio [OR], .5; 95% CI, .2-.9; P = .02) and APRI-defined liver fibrosis (OR, .5; 95% CI, .3-1.0; P = .06) at baseline and/or during follow-up. Most additional associations with HCV viral load also involved HLA class II alleles. Additional associations with FIB-4 and APRI primarily involved class I alleles, for example, the relation of B*1503 with APRI-defined fibrosis had an OR of 2.0 (95% CI, 1.0-3.7; P = .04). CONCLUSIONS: HLA genotype may influence HCV viral load and risk of liver disease, including DQB1*0301, which was associated with HCV clearance in prior studies.
BACKGROUND:Human leukocyte antigen (HLA) class I and II genotype is associated with clearance of hepatitis C virus (HCV) infection, but little is known regarding its relation with HCV viral load or risk of liver disease in patients with persistent HCV infection. METHODS: High-resolution HLA class I and II genotyping was conducted in a prospective cohort of 519 humanimmunodeficiency virus (HIV)-seropositive and 100 HIV-seronegative women with persistent HCV infection. The end points were baseline HCV viral load and 2 noninvasive indexes of liver disease, fibrosis-4 (FIB-4), and the aspartate aminotransferase to platelet ratio index (APRI), measured at baseline and prospectively. RESULTS: DQB1*0301 was associated with low baseline HCV load (β = -.4; 95% confidence interval [CI], -.6 to -.3; P < .00001), as well as with low odds of FIB-4-defined (odds ratio [OR], .5; 95% CI, .2-.9; P = .02) and APRI-defined liver fibrosis (OR, .5; 95% CI, .3-1.0; P = .06) at baseline and/or during follow-up. Most additional associations with HCV viral load also involved HLA class II alleles. Additional associations with FIB-4 and APRI primarily involved class I alleles, for example, the relation of B*1503 with APRI-defined fibrosis had an OR of 2.0 (95% CI, 1.0-3.7; P = .04). CONCLUSIONS: HLA genotype may influence HCV viral load and risk of liver disease, including DQB1*0301, which was associated with HCV clearance in prior studies.
Authors: N Kuzushita; N Hayashi; T Moribe; K Katayama; T Kanto; S Nakatani; T Kaneshige; T Tatsumi; A Ito; K Mochizuki; Y Sasaki; A Kasahara; M Hori Journal: Hepatology Date: 1998-01 Impact factor: 17.425
Authors: Salim I Khakoo; Chloe L Thio; Maureen P Martin; Collin R Brooks; Xiaojiang Gao; Jacquie Astemborski; Jie Cheng; James J Goedert; David Vlahov; Margaret Hilgartner; Steven Cox; Ann-Margeret Little; Graeme J Alexander; Matthew E Cramp; Stephen J O'Brien; William M C Rosenberg; David L Thomas; Mary Carrington Journal: Science Date: 2004-08-06 Impact factor: 47.728
Authors: Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok Journal: Hepatology Date: 2003-08 Impact factor: 17.425
Authors: Susan M McKiernan; Richard Hagan; Michael Curry; George S A McDonald; Alan Kelly; Niamh Nolan; Anne Walsh; John Hegarty; Emer Lawlor; Dermot Kelleher Journal: Hepatology Date: 2004-07 Impact factor: 17.425
Authors: K Yoshizawa; M Ota; S Saito; A Maruyama; T Yamaura; A Rokuhara; K Orii; T Ichijo; A Matsumoto; E Tanaka; K Kiyosawa Journal: Tissue Antigens Date: 2003-02
Authors: Elizabeth Trachtenberg; Bette Korber; Cristina Sollars; Thomas B Kepler; Peter T Hraber; Elizabeth Hayes; Robert Funkhouser; Michael Fugate; James Theiler; Yen S Hsu; Kevin Kunstman; Samuel Wu; John Phair; Henry Erlich; Steven Wolinsky Journal: Nat Med Date: 2003-07 Impact factor: 53.440
Authors: Candelaria Vergara; Margaret M Parker; Liliana Franco; Michael H Cho; Ana V Valencia-Duarte; Terri H Beaty; Priya Duggal Journal: Hum Genet Date: 2018-04-10 Impact factor: 4.132
Authors: Ana Valencia; Candelaria Vergara; Chloe L Thio; Nicolas Vince; Venceslas Douillard; Alba Grifoni; Andrea L Cox; Eric O Johnson; Alex H Kral; James J Goedert; Alessandra Mangia; Valeria Piazzolla; Shruti H Mehta; Gregory D Kirk; Arthur Y Kim; Georg M Lauer; Raymond T Chung; Jennifer C Price; Salim I Khakoo; Laurent Alric; Matthew E Cramp; Sharyne M Donfield; Brian R Edlin; Michael P Busch; Graeme Alexander; Hugo R Rosen; Edward L Murphy; Genevieve L Wojcik; Mary Carrington; Pierre-Antoine Gourraud; Alessandro Sette; David L Thomas; Priya Duggal Journal: Am J Hum Genet Date: 2022-01-31 Impact factor: 11.043
Authors: Andrea A Z Kovacs; Naoko Kono; Chia-Hao Wang; Daidong Wang; Toni Frederick; Eva Operskalski; Phyllis C Tien; Audrey L French; Howard Minkoff; Seble Kassaye; Elizabeth T Golub; Bradley E Aouizerat; Mark H Kuniholm; Joshua Millstein Journal: J Infect Dis Date: 2020-03-16 Impact factor: 5.226
Authors: Alec T McIntosh; Renhuizi Wei; Jaeil Ahn; Brad E Aouizerat; Seble G Kassaye; Michael H Augenbraun; Jennifer C Price; Audrey L French; Stephen J Gange; Kathryn M Anastos; Radoslav Goldman Journal: PLoS One Date: 2021-03-11 Impact factor: 3.240
Authors: Priya Duggal; Chloe L Thio; Genevieve L Wojcik; James J Goedert; Alessandra Mangia; Rachel Latanich; Arthur Y Kim; Georg M Lauer; Raymond T Chung; Marion G Peters; Gregory D Kirk; Shruti H Mehta; Andrea L Cox; Salim I Khakoo; Laurent Alric; Matthew E Cramp; Sharyne M Donfield; Brian R Edlin; Leslie H Tobler; Michael P Busch; Graeme Alexander; Hugo R Rosen; Xiaojiang Gao; Mohamed Abdel-Hamid; Richard Apps; Mary Carrington; David L Thomas Journal: Ann Intern Med Date: 2013-02-19 Impact factor: 25.391
Authors: C Vergara; C Thio; R Latanich; A L Cox; G D Kirk; S H Mehta; M Busch; E L Murphy; M C Villacres; M G Peters; A L French; E Golub; J Eron; C D Lahiri; S Shrestha; D Gustafson; M Young; K Anastos; B Aouizerat; A Y Kim; G Lauer; D L Thomas; P Duggal Journal: Genes Immun Date: 2017-03-16 Impact factor: 2.676